Cholinergic nucleus 4 atrophy and gait impairment in Parkinson’s disease

Background There is evidence that cortical cholinergic denervation contributes to gait and balance impairment in Parkinson’s Disease (PD), especially reduced gait speed. Objectives The objective of this study was to determine the relationship between cholinergic basal forebrain gray matter density (GMD) and gait in PD patients. Methods We investigated 66 PD patients who underwent a pre-surgical evaluation for a neurosurgical procedure to treat motor symptoms of PD. As part of this evaluation patients had a brain MRI and formal gait assessments. By applying probabilistic maps of the cholinergic basal forebrain to voxel-based morphometry of brain MRI, we calculated gray matter density (GMD) for cholinergic nucleus 4 (Ch4), cholinergic nucleus 1, 2, and 3 (Ch123), and the entire cortex. Results Reduced Ch4 GMD was associated with reduced Fast Walking Speed in the “on” medication state (FWSON, p = 0.004). Bilateral cortical GMD was also associated with FWSON ( p = 0.009), but Ch123 GMD was not ( p = 0.1). Bilateral cortical GMD was not associated with FWSON after adjusting for Ch4 GMD ( p = 0.44). While Ch4 GMD was not associated with improvement in Timed Up and Go (TUG) or Cognitive TUG in the “on” medication state, reduced Ch4 GMD was associated with greater percent worsening based on dual tasks ( p = 0.021). Conclusions Reduced Ch4 GMD is associated with slower gait speed in PD and greater percent worsening in TUG during dual tasks in patients with PD. These findings have implications for planning of future clinical trials investigating cholinergic therapies to improve gait impairment in PD.